Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization

Mohammad Ali Sadiq, Mostafa Hanout, Salman Sarwar, Muhammad Hassan, Diana V. Do, Quan Dong Nguyen, Yasir Jamal Sepah

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy (DR), retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factor (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF plays an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly AMD, has become more exciting due to agents such as PDGF antagonists.

Original languageEnglish (US)
Pages (from-to)287-291
Number of pages5
JournalSaudi Journal of Ophthalmology
Issue number4
StatePublished - 2015


  • Age related macular degeneration
  • Diabetic retinopathy
  • PDGF
  • Platelet derived growth factor
  • Retinal vascular disease

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization'. Together they form a unique fingerprint.

Cite this